Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR (R1DY34) Stock Price & Analysis

R1DY34 Stock Chart & Stats

$12.84$0.50(4.05%)

At close: Oct 30

Day’s Range: $12.84 - $12.86
52-Week Range: $0.01 - $13.56
Previous Close: $12.34
Volume: N/A
Average Volume (3M): 85
Market Cap: BRL 64.56B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.36
Next Earnings: Jan 22, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR News

Improving Margins and EPS Upgrades Offset by Full Valuation, Supporting Hold Rating

Jefferies analyst Alok Dalal upgraded the rating on Dr. Reddy’s Laboratories Ltd. to a Hold yesterday, setting a price target of INR1,320.00. Alok Dalal has given his Hold rating due

6d agoRDY RDDA

Dr. Reddy’s upgraded to Hold from Underperform at Jefferies

Jefferies upgraded Dr. Reddy’s (RDY) to Hold from Underperform with a price target of $13.90, up from $11.40, following the September quarter EBITDA beat. The firm cites higher margins for

1w agoRDY RDDA

Dr. Reddy’s upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Dr. Reddy’s (RDY) to Neutral from Underweight with a price target of INR 1,270, up from INR 1,100. The firm sees a more balanced risk/reward following the company’s

1w agoRDY RDDA

Dr. Reddy’s upgraded to Outperform from Neutral at BNP Paribas

BNP Paribas analyst Tausif Shaikh upgraded Dr. Reddy’s (RDY) to Outperform from Neutral with a $14.80 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking

2w agoRDY RDDA

Dr. Reddy’s double-upgraded to Buy from Sell at Citi

Citi analyst Vivek Agrawal upgraded Dr. Reddy’s (RDY) to Buy from Sell with a price target of INR 1,450, up from INR 1,040. While North America revenues are expected to

1M agoRDY RDDA

Immutep provides update on development strategy for eftilagimod alfa

Immutep (IMMP) provided an update on its development strategy for eftilagimod alfa. Following the early discontinuation of the TACTI-004 study, Immutep has been conducting a detailed root cause analysis covering

1M agoRDY IMMP

Dr. Reddy’s says FDA inspection of UK facility ‘officially closed’

Dr. Reddy’s (RDY) announced that the FDA’s inspection of its West Yorkshire, United Kingdom manufacturing facility is “officially closed.” Published first on TheFly – the ultimate source for real-time, market-moving

2M agoRDY RDDA

Fresenius announces FDA approval of rituximab biosimilar

Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories, a biosimilar to Rituxan.

3M agoRDY FRE

R1DY34 FAQ

What was Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR’s price range in the past 12 months?

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR lowest stock price was $0.01 and its highest was $13.56 in the past 12 months.

What is Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR’s market cap?

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR’s market cap is R$64.56B.

When is Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR pay dividends?

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR does not currently pay dividends.

What is Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR’s EPS estimate?

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR have?

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR has 834,641,240 shares outstanding.

Which hedge fund is a major shareholder of Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR?

Currently, no hedge funds are holding shares in BR:R1DY34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR (R1DY34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	6
Technical Analysis	3	1	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:R1DY34
Company	Price & Change	Follow
BR:A2RR34Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
BR:B1AX34Baxter International Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh
BR:B1MR34Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
BR:R2GE34Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh
BR:T1CH34Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh

Compare BR:R1DY34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft